

1 Dalmore Drive,
Scoresby,
Victoria 3179
AUSTRALIA
T: +61 (0)3 9763-1287
F: +61 (0)3 9763-2817
www.generabiosystems.com

Friday 16 February 2018

**ASX Announcement – GENERA BIOSYSTEMS LIMITED (ASX: GBI)
GLOBAL IVD PARTNERSHIP UPDATE**

Genera Biosystems Limited (**‘Genera’**) is pleased to provide an update regarding the proposed global IVD partnership with Beckman Coulter.

In early December 2017, the Board was delighted to announce that Genera would enter into a co-marketing partnership with Beckman Coulter Life Sciences, a leader in the fields of automation and flow cytometry (**see Genera ASX announcement of 6 December for further detail of this partnership**).


In its 31 January market update, Genera advised that the legal process for entry into the partnership was nearing completion and that it expected to formally execute the agreement during the week commencing 5 February.

For a number of internal reasons within Beckman Coulter and the wider Danaher Life Sciences group the indicative timeline for completion has been slightly extended. Genera continues to have positive and collegiate dialogue with the senior Beckman executives liaising with the regulatory compliance and legal teams at Beckman Coulter and Danaher Life Sciences as we work together to finalise all necessary arrangements.

Genera will announce to the market via the ASX platform as soon as the relevant partnership agreement is executed.

For further information please contact:

Mr Richard Hannebery
Chief Executive Officer
Genera Biosystems Limited
Telephone: +61 (0)3 9763 1287
www.generabiosystems.com.au



About Genera Biosystems : Genera Biosystems Limited (“GBI”) is an Australian Securities Exchange listed molecular diagnostics company, which develops, manufactures and distributes advanced PCR molecular diagnostics tests. Genera has successfully developed two products to date, PapType® and RTI-Plex™, both of which are CE-IVD marked with several additional products in the company’s development pipeline.

Genera’s single-well high multiplex AmpaSand® testing platform can detect up to 125 target analytes in a single-well of a reaction plate. Unlike traditional real-time PCR approaches, AmpaSand® single-well multiplex tests when run on a seamlessly integrated flow cytometry and liquid handling system can provide unparalleled throughput capability and cost efficiency for high volume pathology laboratories qualitative molecular testing needs.

Genera manufactures products in its Australian Therapeutics Goods Administration certified manufacturing facility in Scoresby, Victoria, Australia.